Study links DPP-IV medication to heart failure, hospitalization

Share this article:

A study of Merck's diabetes DPP-IV medication Januvia indicates the treatment may be associated with an increased risk of heart failure coupled with hospitalization. Forbes reports that although a related editorial describes the absolute risk of heart failure with the DPP-IV as “if present at all, appears to be small,” the study's researchers write that the finding could be clinically relevant.

This is the second bit of recent concern for the drug class as a whole–the medications have been scrutinized over the last year-and-a-half over concerns that they could cause pancreatitis, an inflammation which is associated with pancreatic cancer. Regulators in the US and Europe released a middle-of-the-road assessment in February in which neither group could say there was a causal relationship between the drugs and pancreatitis and/or pancreatic cancer, but were going to keep an eye on future data.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.